Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Proceedings

Open Access

Cytotoxicity evaluation of curcumin treatment in DH82 canine histiocytic sarcoma cell line

  • Natália Noronha1,
  • Gabriel Silva1,
  • Ana Lucia Fachin1 and
  • Mozart Marins1
BMC Proceedings20148(Suppl 4):P138

https://doi.org/10.1186/1753-6561-8-S4-P138

Published: 1 October 2014

Background

The identification of targets and new drugs to fight cancer is one the greatest challenges for Biotechnology researchers. Not only humans, but also animals are affected by this disease. It is estimated for example that one in every 3-4 dogs will develop some type of cancer during its lifetime, twice as much as the human being [1, 2]. DNA methylation is an important epigenetic mechanism which control gene expression during cell proliferation and differentiation. Deregulation of this mechanism is one of the events which can contribute to the development of cancer [3]. The identification of epigenetic drugs, which are molecules that can revert aberrant DNA methylation, is one of the main areas of cancer research nowadays. In this regard, natural products are a rich source of possibilities to increase the arsenal of epigenetic drugs [1]. This study aims to analyze the cytotoxicity effect of curcumin treatments in DH82 canine histiocytic sarcoma cell line. This polyphenol derived from Curcuma longa has emerged as a potent multimodal cancer-preventing agent which modulates multiple cell signaling pathways and also been described as an inhibitor of DNA methylation[4]. The knowledge of the biological effects of these substances can pinpoint targets for the development of epigenetic drugs, with a positive impact for the treatment of canine and human cancer.

Materials and methods

DH82 cells grew under 37°C and 5% CO2, DMEM medium was supplemented with 10% Bovine Fetal Serum. To estimate DH82 viability and curcumin cytotoxicity, the MTT protocol was performed at a concentration of 2 × 105 cells/well cultured in 96 well plates. After each treatment, the cells were incubated during four hours with a 5 μg/mL MTT (3 - (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) solution. Lastly the MTT salt conversion to formazan crystals was quantified by spectrophotometry.

A curcumin therapeutic dose curve was established at 24, 48 and 72 hours treatments.

Results and discussions

In 24 hours, the IC50 was 21.88µg/mL (59.4µM), in 48 hours was 14.26µg/mL (38.7µM) and in 72 hours was 12.17µg/mL (33.0µM). A range of values were obtained and the dispersion, especially on IC50 coordinate coincides with the trend line, showing good positive correlation.

Conclusions

The DH82 cell line demonstrated susceptibility to treatments with curcumin, which reflects the importance of this natural product as a tool for the development of new epigenetic drugs which could be also explored to fight cancer in pet dogs.

Financial support

This study was supported by grants from Research Foundation of the State of São Paulo (FAPESP - 2012/23333-2).

Authors’ Affiliations

(1)
Department of Biotechnology, University of Ribeirão Preto

References

  1. Baek SJ, McEntee MF, Legendre AM: Review paper: Cancer chemopreventive compounds and canine cancer. Veterinary pathology. 2009, 46: 576-588.View ArticlePubMedGoogle Scholar
  2. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G, Bocchini V: Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2008, 22: 976-984.View ArticlePubMedGoogle Scholar
  3. Ma X, Wang YW, Zhang MQ, Gazdar AF: DNA methylation data analysis and its application to cancer research. Epigenomics. 2013, 5: 301-316.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Fu S, Kurzrock R: Development of curcumin as an epigenetic agent. Cancer. 2010, 116: 4670-4676.View ArticlePubMedGoogle Scholar

Copyright

© Noronha et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement